Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked nucleic acid PCR clamp, and patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2006-12, Vol.95 (11), p.1483-1489
Hauptverfasser:	Sutani, A, Nagai, Y, Udagawa, K, Uchida, Y, Koyama, N, Murayama, Y, Tanaka, T, Miyazawa, H, Nagata, M, Kanazawa, M, Hagiwara, K, Kobayashi, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Chemotherapy Clinical Study DNA Mutational Analysis Drug Resistance Drug Resistance, Neoplasm - genetics Epidemiology Epidermal growth factor receptors Female Gefitinib Genes, erbB-1 Humans Internet Liver Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - mortality Male Medical sciences Middle Aged Molecular Medicine Mutation nucleic acids Oncology Peptide Nucleic Acids - genetics Pneumology Point mutation Polymerase chain reaction Polymerase Chain Reaction - methods Prognosis Quinazolines - therapeutic use Skin Survival Survival Analysis Toxicity Tumors Tumors of the respiratory system and mediastinum
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!